Prostacycline and the ARDS Population

We strongly believe that this therapy may be helpful for patients with ARDS and we are actively seeking funds to enable us to run a large scale randomized controlled trial in ARDS patients. We've seen that COVID has changed certainly the clinical effects that we see the pathophysiology appears to have changed across the different waves of SARS-CoV-2. And how would you manage the heterogeneity of ARDS? I mean famously it's been reported in autopsy studies and in biopsy studies that about half the patients with AR DS don't have diffused all the other damage. Will you deal with that? Or do you think that maybe prostacyton may just be effective for all critical patients